Emily Erbelding | |
---|---|
Born | 1961 (age 61–62) |
Alma mater | Cornell University (BA, MS) Indiana University School of Medicine (MD) Johns Hopkins Bloomberg School of Public Health (MPH) |
Scientific career | |
Fields | Infectious diseases |
Institutions | Johns Hopkins School of Medicine National Institute of Allergy and Infectious Diseases |
Emily J. Erbelding (born 1961) [1] is an American physician-scientist. She is the director of the Division of Microbiology and Infectious Diseases at the National Institute of Allergy and Infectious Diseases (NIAID). Erbelding was previously deputy director of the Division of AIDS at NIAID. She was a faculty member at Johns Hopkins School of Medicine and served as director of clinical services for the Baltimore City Health Department STD/HIV program.
Erbelding graduated cum laude from Cornell University, where she also received a master of science degree. [2] Her 1985 master's thesis was titled Glutamine metabolism in the small intestine. [1] She earned her medical degree from Indiana University School of Medicine and completed her residency in internal medicine at Northwestern University Medical Center, serving as chief medical resident. While completing a fellowship in infectious diseases at the Johns Hopkins Hospital, she also earned a Master of Public Health degree with a concentration in epidemiology from the Johns Hopkins Bloomberg School of Public Health. [2] [3]
Erbelding spent 14 years on the faculty of the Johns Hopkins School of Medicine, in the division of infectious diseases, and was the director of clinical services for the Baltimore City Health Department STD/HIV program. [2] [3]
Erbelding served as deputy director of the Division of AIDS at the National Institute of Allergy and Infectious Diseases (NIAID). There she was involved in all aspects of scientific program management and support, helping to design and implement new initiatives involving basic, translational and clinical research and administering complex extramural grant programs and research infrastructure. [2]
In 2017, Erbelding became director of the NIAID Division of Microbiology and Infectious Diseases (DMID). She is responsible for the strategic and scientific vision for DMID's complex national and international research program. DMID supports basic, preclinical, and clinical investigations into the causes, diagnosis, treatment, and prevention of a broad range of pathogens, including those related to biodefense and emerging infectious diseases. [2] [3]
Erbelding serves on the acute flaccid myelitis task force at the Centers for Disease Control and Prevention. [4]
The National Institute of Allergy and Infectious Diseases is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.
The Vaccine Research Center (VRC), is an intramural division of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), US Department of Health and Human Services (HHS). The mission of the VRC is to discover and develop both vaccines and antibody-based products that target infectious diseases.
Barton Ford Haynes is an American physician and immunologist internationally recognized for work in T-cell immunology, retrovirology, and HIV vaccine development. Haynes is a Frederic M. Hanes Professor of Medicine and Immunology at Duke University Medical Center. He is the director of the Duke Human Vaccine Institute and the Duke Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery (CHAVI-ID), which was funded by the National Institute of Allergy and Infectious Diseases (NIAID) in 2012. In addition, Haynes directs the B-cell Lineage Envelope Design Study, the Centralized Envelope Phase I Study, and the Role of IgA in HIV-1 Protection Study as part of the Collaboration for AIDS Vaccine Discovery (CAVD), which was funded by the Bill and Melinda Gates Foundation in 2006.
Jeffrey P. Nadler is an American Infectious Diseases and HIV/AIDS expert. His most recent position has been as Acting Director and Assistant Director of the Therapeutics Research Program, Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases (NIAID) where he oversaw NIH/NIAID-sponsored national and international HIV/AIDS research.
Kathryn C. Zoon is a U.S.-based immunologist, elected to the U.S. Institute of Medicine in 2002 for her research on human interferons. She is the former scientific director of the Division of Intramural Research at the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) in Bethesda, Maryland. From 1992 to 2002, Zoon was director of the FDA Center for Biologics Evaluation and Research (CBER).
Lauren V. Wood is an American allergist, immunologist, and staff physician at the National Cancer Institute (NCI) at the National Institutes of Health (NIH) in Bethesda, Maryland, where she has served as a principal investigator. She is known for conducting studies of vaccines for cancer, Human papillomavirus (HPV), Hepatitis C, and HIV especially for use with children, teens and young adults. She holds the rank of captain in the U.S. Public Health Service (PHS).
Julie E. Ledgerwood is an American allergist and immunologist, who is the chief medical officer and serves as chief of the Clinical Trials Program at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health in Bethesda, Maryland. She is a Doctor of Osteopathic Medicine.
Thomas Charles Merigan was born January 18, 1934 in San Francisco. He is an American virologist and the George E. and Lucy Becker Professor of Medicine, Emeritus at the Stanford University School of Medicine. Merigan's research first focused on human viral pathogenesis, basic and clinical studies of interferon, and then developing the first systemically active antiviral drugs including those effectively treatIng HIV/AIDS, several herpesviruses and hepatitis B. He is also credited with helping to develop the use of interferons as antiviral, immunomodulating and antitumor therapies. Merigan joined the Stanford faculty in 1963 and assumed full emeritus status in 2007. In 2004 he was also identified as one of the 250 most cited investigators in clinical medicine over the last 20 years by the Institute for Scientific Information. Merigan also was ranked 23rd among the 1000 top US microbiologists by Research.com in 2022. His papers have been cited over 45,000 times. He had over 95 postdoctoral fellows, students and visiting scientists with whom he published 577 papers, 24 books monographs and published symposia, and held 11 US patents. Two of his books went into multiple editions- one into a 4th edition and the other into a 3rd. His students have become leaders in the fields of infectious diseases and microbiology both in the US and the world. Seven of his students subsequently joined the Stanford medical faculty. He was a board member of 28 journals and a member of 23 learned societies. He told his life story in a book entitled Pioneering Viral Therapy,a Life in Academic Medicine, published by Amazon/Kindle/CreateSpace in 2017.
John Eugene Bennett is an American physician-scientist. He is a senior investigator in the clinical mycology section in the intramural research program at the National Institute of Allergy and Infectious Diseases.
Patrizia Farci is an Italian scientist and hepatologist. She is chief of the hepatic pathogenesis section at the National Institute of Allergy and Infectious Diseases. Farci conducts translational research in the field of liver diseases, particularly in the study of pathogenesis of acute and chronic viral hepatitis. She was previously a full professor of medicine and director of the liver unit and the postgraduate school of gastroenterology at the University of Cagliari.
Irini Sereti is a Greek scientist and physician. She is chief of the HIV pathogenesis section at the National Institute of Allergy and Infectious Diseases. Sereti researches immune reconstitution inflammatory syndrome, idiopathic CD4 lymphocytopenia, and immune-based therapeutic strategies of HIV investigation.
Jeanne M. Marrazzo is an American physician-scientist and infectious diseases specialist. She is the director of the University of Alabama School of Medicine Division of Infectious Diseases and focuses on prevention of HIV infection using biomedical interventions. Marrazzo is also a fellow of the American College of Physicians and Infectious Disease Society of America. On August 2, 2023 Lawrence A. Tabak, acting director for the National Institutes of Health, named Jeanne M. Marrazzo as director of NIH’s National Institute of Allergy and Infectious Diseases.
Kimberly Y. Smith is an American scientific executive and medical doctor serving as the head of research and development at ViiV Healthcare.
Kelly Anne Gebo is an American epidemiologist and infectious disease specialist. She was the inaugural Vice Provost for Education at Johns Hopkins University and served as the Chief Medical and Scientific Officer for the All of Us Research Program at the National Institutes of Health.
Dr. Michael J. Lenardo, is the chief of the Molecular Development and Immune System Section and the founder and co-Director of the Clinical Genomics Program at the National Institute of Allergy and Infectious Disease (NIAID), National Institutes of Health (NIH). Trained as a geneticist, molecular biologist, and immunologist, his research examines how cells of the immune system defend themselves against various pathogens, including viruses and bacteria. His research has investigated genetic abnormalities in the immune system, mechanisms of cell death, genetic diseases of immune homeostasis and autoimmunity, and development of novel diagnostics and therapeutics for diseases of the immune system. Lenardo's contributions to science and medicine have shown the possibilities of genomic research in developing precision medicine diagnoses and treatments for disease in humans. In 2006 he was appointed Officer of the Most Excellent Order of the British Empire (O.B.E.) by Queen Elizabeth II. In 2019 he was inducted into the National Academies of Sciences and the National Academy of Medicine, considered among the highest honors awarded to a U.S scientist and medical researcher respectively.
Hugh Auchincloss, Jr., is an American immunologist and physician serving as the acting director of the National Institute of Allergy and Infectious Diseases since 2023. He previously served as the principal deputy director between 2006 and 2022. He was previously a transplant surgeon and professor of surgery at Harvard Medical School, and researched at Massachusetts General Hospital for 17 years.
John Ring La Montagne was a Mexican-American biomedical scientist who served as the deputy director of the National Institute of Allergy and Infectious Diseases from 1998 to 2004. He specialized in viral vaccines, HIV/AIDS research, and oversaw NIH's biodefense research after the September 11 attacks.
Tara N. Palmore is an American physician-scientist and epidemiologist specializing in patient safety through prevention of hospital-acquired infections. As of 2021 she was the hospital epidemiologist at George Washington University School of Medicine and Health Sciences.
John R. Mascola is an American physician-scientist, immunologist and infectious disease specialist. He was the director of the Vaccine Research Center (VRC), part of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH). He also served as a principal advisor to Anthony Fauci, director of NIAID, on vaccines and biomedical research affairs. Mascola is the current Chief Scientific Officer for ModeX Therapeutics.